Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (nk-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: simlukafusp alfa, pegenzileukin, aldesleukin +7 | 0.72 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 326 | 0.85 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 12713
Sealed predictions
- IL2RB in dopamine neurons, braak-0.23 (p 0.554) → -0.42 (p 0.258)receipt 12720
Swarm cases
receipt 12720: IL2RB in dopamine neurons, braak
- power
- full sample -0.28 (p 0.261, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.27 (p 0.273, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.118, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.20, sign flips 0; without severely affected donors -0.28 (p 0.261, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL2RB in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts